Brokers Set Expectations for BioVie Q3 Earnings

BioVie Inc. (NASDAQ:BIVI) – Research analysts at Brookline Capital Management issued their Q3 2025 earnings per share estimates for shares of BioVie in a research report issued on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian expects that the company will earn ($0.32) per share for the quarter. Brookline Capital Management has a “Strong-Buy” rating on the stock. Brookline Capital Management also issued estimates for BioVie’s Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.63) EPS.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.46) earnings per share (EPS) for the quarter.

BioVie Stock Down 2.6 %

BIVI stock opened at $1.12 on Friday. The business’s fifty day moving average is $1.60 and its 200-day moving average is $2.12. The company has a market cap of $20.67 million, a P/E ratio of -0.11 and a beta of 0.51. BioVie has a twelve month low of $0.99 and a twelve month high of $7.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC lifted its stake in shares of BioVie by 14,000.0% in the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock valued at $28,000 after purchasing an additional 14,000 shares during the period. Squarepoint Ops LLC acquired a new position in shares of BioVie in the 4th quarter valued at $28,000. Northern Trust Corp acquired a new position in shares of BioVie in the 4th quarter valued at $34,000. Two Sigma Investments LP acquired a new position in shares of BioVie in the 4th quarter valued at $57,000. Finally, Prosperity Wealth Management Inc. acquired a new position in shares of BioVie in the 4th quarter valued at $63,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.